BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Aikening (Albuvirtide) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Aikening (Albuvirtide)\, from ClinicalTri
 als.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07727642-988@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Aikening (Albuvirtide): Phase na readout est. (NCT07727642)
DESCRIPTION:Aikening (Albuvirtide)\, phase na\, HIV.\nStudy: Optimization o
 f Antiretroviral Therapy in Patients With AIDS-Related Lymphoma\nEstimated
  primary completion: July 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/albuvirtide#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07727642
URL:https://assetmemo.bio/drug/albuvirtide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
